Antibody-Drug Conjugates
Antibody-Drug Conjugates (ADCs) are innovative cancer treatments that combine a targeted therapy with chemotherapy. They consist of an antibody, which is a protein that can specifically recognize and bind to cancer cells, linked to a toxic drug that kills those cells. When the ADC enters the body, the antibody seeks out and attaches to the cancer cells, delivering the drug directly to them while sparing healthy cells. This targeted approach aims to maximize the effectiveness of the treatment while minimizing side effects, making ADCs a promising option in cancer therapy.
Additional Insights
-
Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combines an antibody with a cytotoxic (cell-killing) drug. The antibody specifically recognizes and binds to cancer cells, allowing the attached drug to be delivered directly to those cells. This targeted approach helps minimize damage to healthy cells, reducing side effects. Once inside the cancer cell, the drug is released, effectively killing the cell. ADCs represent a more precise method of treatment, aiming to improve the efficacy of chemotherapy while limiting harm to normal tissues.